The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen. by Mercadante, S. et al.
The Use of Opioids for Breakthrough Pain in Acute
Palliative Care Unit by Using Doses Proportional
to Opioid Basal Regimen
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Objectives: To determine the eﬃcacy and safety of diﬀerent opioids
used in doses proportional to the basal opioid regimen for the
management of breakthrough pain (BP).
Methods: In 66 patients consecutive patients admitted to a pain
relief and palliative care unit, the eﬃcacy and safety of diﬀerent
opioids used in doses proportional to the basal opioid regimen for
the management of breakthrough pain (BP) were assessed. The
choice of the opioid to be administered as rescue medication was
based on the characteristics of patients, clinical stability, compliance,
preference, and so on. For each episode, nurses were instructed to
routinely collect changes in pain intensity and emerging problems
when pain became severe (T0), and to re-assess the patient 15
minutes after the opioid given as a rescue medication (T15).
Results: Six hundred twenty four episodes of BP were recorded
during admission. Intravenous morphine (IV-MO) and oral
transmucosal fentanyl (OTFC) were most frequently administered.
Of 503 events available, 427 episodes were deﬁned as successfully
treated, while 76 episodes required a further administration of
opioids. Pain intensity signiﬁcantly decreased at T15 in all the
groups (P<0.001). In 97.2% and 90.7% of cases treated with IV-
MO, BP events had a reduction in pain intensity of more than 33%
and 50%, respectively. In 99.2% and 97.6% patients receiving
OTFC, BP events had a reduction in pain intensity of more than
33% and 50%, respectively.
Discussion: This survey suggests that doses of opioids for BP
proportional to the basal opioid regimen, are very eﬀective and safe
in clinical practice, regardless the opioid and modality used.
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In the cancer population, breakthrough pain (BTP) is atransitory exacerbation of the pain superimposed on an
otherwise stable pain pattern in patients treated with
opioids.1 BTP is normally severe in intensity and has a
rapid onset. The presence of BTP has been considered as a
negative prognostic factor that interfered with the quality
of life of the patients.2 Availability of supplemental doses of
opioids (rescue medication) in addition to the continuous
analgesic medication is the main treatment suggested to
manage these pain ﬂares, either during dose titration or
when basal pain is under control. Current dosing recom-
mendations for BTP generally suggest that the eﬀective
dose of BTP medication must be a percentage of a patient’s
total daily opioid dose.3 These recommendations, which are
based entirely on anecdotal experience, favor the selection
of a short-acting opioid at a dose proportional to the total
daily dose. As the pain relief is usually required urgently,
routes of administration designed to delivery drugs rapidly
are often chosen. A short onset of the eﬀect is commonly
obtainable only with parenteral or transmucosal adminis-
tration of opioid analgesics.
In preliminary experiences, intravenous morphine (IV-
MO) proved to be safe and eﬀective for the management of
BTP4,5 and has been the preferred treatment in the last
5 years in our acute pain relief and palliative care unit. In
studies of the oral transmucosal fentanyl citrate (OTFC),6–9
the anecdotal assumption that the eﬀective dose as needed
is a percentage of the opioid daily dose was contradicted by
the observation that the OTFC dose needs to be titrated,
introducing a new variable in choosing the doses to be
administered, which could reduce patient’s and physician’s
compliance. The need for titration may discourage patients,
particularly outpatients or home care patients, to continue
titration in daily activity. In an earlier open controlled
study, both IV-MO and OTFC in doses proportional to the
scheduled daily dose of opioids were safe and eﬀective in
patients experiencing pain exacerbation,10 suggesting that
opioids given as needed, including OTFC, could be safely
used at proportional doses, regardless of the modality
of administration. Finally, indirect observations from data
pooled from trials of OTFC showed a relationship between
the BTP dose and around-the-clock dose, despite large
variability in patients’ dose requirements.11 The aim of this
audit was to conﬁrm the safety of such an approach with
the available formulations of opioids commonly used for
treating BTP in our country, avoiding the process of dose
titration for BTP in a large number of patients assessed in a
real clinical scenario representing the routine activity of an
acute palliative care unit.
METHODS
All the patients consecutively admitted to a Pain Relief
and Palliative Care unit in a period of 6 months from
January 2008 to June 2008 were surveyed. From this
sample, patients who were receiving opioids in doses of oral
morphine equivalents equal to or more than 60mg daily,Copyright r 2010 by Lippincott Williams & Wilkins
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who were prescribed opioids for BTP of diﬀerent nature,
were included into the study. Informed consent for record-
ing data for the study from all patients and institutional
approval were obtained.
Patients were treated according to the department
policy. After establishing around-the-clock opioid medica-
tion, according to opioid titration process, patients were
encouraged to call when their pain got severe either during
the titration phase or when basal pain was controlled
(considered when the mean pain intensity is equal or less
than 4/10) and superimposed episodes of BTP occur.
The choice of opioids for basal pain and BTP was
based on clinical judgment, according to diﬀerent factors,
including the patient’s characteristics, clinical needs, patients’
compliance, opioid used for background analgesia, and pre-
ference. Department’s policy suggests that the dose to be given
was proportional to the dose administered for background
analgesia, 1/5 of the oral morphine equivalent to daily
doses, taking into account also the route conversion ratios.4
For example, a daily oral morphine dose 60mg corresponds
to an intravenous dose of 20mg (1/3 ratio), and then is con-
verted to 4mg of the intravenous morphine (1/5) as the
dose for BTP. Similarly, oral morphine (OR-MO) is 12mg
and OTFC is 200mg. Doses of the other opioids, oral
oxycodone (OR-OX), oral methadone (OR-ME), and intra-
venous methadone (IV-ME), also used for treating BTP,
were adapted using conversion ratios routinely adopted by
the unit (Table 1).4 The opioid dose is modiﬁed according
to eventual changes of the daily oral morphine dosage.
Written orders for BTP, including drugs and doses to be
administered when pain gets severe enough are routinely
given in the therapy chart. For each episode, trained nurses
recorded pain intensity (numerical scale 0 to 10) and
adverse eﬀects severe enough in intensity to require medical
intervention, when called for pain increases considered to
be severe in intensity by patients (T0), and 15 minutes after
administering the rescue dose of opioids (T15).5 The
administration of BTP opioid medication was considered
unsuccessful whenever a further BTP medication was
required in the subsequent 2 hours. As a routine, a physician
on duty is present in the department, and the palliative care
team is available on call for any emergency or consultation
in case of development of severe adverse eﬀects. The
principal outcome was the evaluation of the number of
patients who could beneﬁt from opioids given as rescue
medication within 15 minutes, a clinically meaningful time
to evaluate a dose administered as needed, using propor-
tional doses of the basal opioid dosage, regardless of the
opioid and modality used and the occurrence of adverse
eﬀects severe enough in intensity to require medical
intervention.
Statistical Analysis
Patients were divided according to the age: r65 years
and >65 years. Frequency analysis was carried out using
the w2 test. Frequency analysis was carried out using the
Pearson chi-square test and Fisher exact test. The 1-way
analysis of variance and Kruskal-Wallis Statistic test were
used to compare the diﬀerent parametric or nonparametric
variables. Data were analyzed by SPSS Software 14.0
version (SPSS, Inc., Chicago, Ill, US). All P-values were
2 sided, and P values less than 0.05 were considered
statistically signiﬁcant.
RESULTS
Sixty-six patients were surveyed. The mean age was
66.7 (±12.2), and 39 (59.1%) of the patients were over
65 years. Forty-two patients were male. Opioids used for
background analgesia were in a rank order: buprenorphine
(18), fentanyl (16), IV-MO (11), OR-OX (10), OR-MO (6),
hydromorphone (4), and OR-ME (1). Six hundred twenty-
four episodes of BTP were recorded during admission
(5.3 d, SD±3.6). Each patient presented a mean of 8.7
(SD±8) episodes during admission (median 2 episodes/d).
IV-MO and OTFC were most frequently administered.
Three hundred eighty-six, 152, 42, 5, 32, and 7 episodes
were treated with IV-MO, OTFC, OR-MO, OR-ME,
IV-ME, and OR-OX, respectively. In 121 events, docu-
mentation regarding changes in pain intensity was incom-
plete in the record sheet (67 and 54 events were incomplete
at T0 and T15, respectively). Of the 503 valuable episodes,
427 were successful treated without any further request,
whereas 76 episodes (15.1%) required a further adminis-
tration of opioids within the subsequent 2 hours.
Pain intensity signiﬁcantly decreased at T15 in all the
groups, Pr0.001 (Table 2), regardless of the drug and
modality used. In 241 (97.2%) and 225 (90.7%) episodes
occurring in patients receiving IV-MO, BTP events had a
reduction in pain intensity of more than 33% and 50%,
respectively. In 123 (99.2%) and 121 (97.6%) of episodes
occurring in patients receiving OTFC, BTP events had
a reduction in pain intensity of more than 33% and 50%,
respectively. Data regarding other opioids are listed in
Table 3. Cumulative percentages of responders are reported
in Figure 1.
No diﬀerences in gender and age and percentage
changes of pain intensity were observed (P=0.383 and
P=0.788, for 33% and 50% of pain reduction, respec-
tively, for gender, and P=0.288 and P=0.218, respec-
tively, for age). No adverse eﬀects, severe enough in
intensity to require medical intervention, were observed.
DISCUSSION
The opioid dose to be administered for BTP is still
controversial. Owing to the variability in the presentation
of pain ﬂares, it is diﬃcult to provide clear guidelines.12
Dosing recommendations for morphine have been based on
anecdotal experience; they suggest that the eﬀective dose of
BTP medication is a percentage of the patient’s total daily
opioid dose. EAPC recommendations suggest 1/6 (17%) of
the daily dose as a starting point.3 On the other hand, all
the trials with OTFC have contradicted this anecdotal








The opioid dose for BTP is 1/5 of the oral morphine equivalent daily
doses, also taking into account route conversion ratios (see example in
Methods).4
IV-ME indicates intravenous methadone; IV-MO, intravenous mor-
phine; OR-ME, oral methadone; OR-MO, oral morphine; OR-OX, oral
oxycodone; TTS-fentanyl, transdermal fentanyl.
Clin J Pain  Volume 26, Number 4, May 2010 The Use of Opioids for Breakthrough Pain
r 2010 Lippincott Williams & Wilkins www.clinicalpain.com | 307
assumption drawn from practical experience, suggesting a
lack of relationship between the eﬀective OTFC dose and
ﬁxed schedule of opioid regimen, regardless of the opioid
used.6–9 However, observations from data pooled from
these trials of OTFC showed a statistically signiﬁcant
relationship between the BTP dose and around-the-clock
dose, despite an enormous interindividual variability in
patients’ dose requirements.11 Other studies with IV-MO
have shown that IV-MO given as BTP medication in doses
proportional to opioid basal regimen is safe and eﬀective,4
and this observation was replied in a conﬁrmatory study of
a large number of episodes of BTP pain without evident
risks even in aged population.5 As IV-MO has the highest
potential risk for serious adverse event, one could argue
that other drugs should be at least similarly safe. In a recent
controlled study, similarly to IV-MO, OTFC used at a dose
proportional to the basal opioid regimen was safe and
eﬀective in the majority of patients experiencing pain
exacerbation.10
In this audit, reproducing a typical clinical scenario
of an acute pain relief and palliative care unit, in which
treatment is highly individualized, and diﬀerent options are
oﬀered to patients according to the clinical need, opioids
were given as BTP medication according to a construct
based on the level of opioid tolerance provided by doses
of opioids received for background analgesia. Thus, a
dose proportional to the basal opioid regimen is given to
counteract the increasing pain intensity. The intent of the
study was not comparative, because opioids were freely
chosen according to the clinical proﬁle of each patient, and
the aim was not to ﬁnd the fastest and eﬀective drug. For
each patient, opioids were chosen according to individual
needs, based on clinical judgment, including BTP presenta-
tion, type of opioid for background analgesia, patients’
preference. For example, IV-ME or OR-ME were more
frequently used in patients receiving methadone analgesia,
oral route was used in patients with slow onset or nonsevere
BTP intensity or simply because of patients’ preference in
respect to OTFC. Parenteral route or OTFC were chosen in
patients who were unable to swallow or with nausea, or
requiring prompt analgesia when more episodes occurred
before achieving a stable basal dose. Although this group of
patients should not be considered as having BTP, the
treatment is otherwise the same. Thus, more often a
compromise between clinical needs and patient preference
was driving the decision. As expected IV-MO and OTFC,
were the most frequent BTP medications used for BTP.
We also analyzed recently reported data according to
the concept of cumulative response,13 which provide even
more information about the number of patients with
diﬀerent percentage decreases in pain intensity in respect
to earlier common cut-oﬀ of 33% and 50%.14 This study
did not have comparative purposes and the results are
obviously related to the choices dictated by the clinical
judgment, rather than a comparison using homogeneous
protocols. An individual treatment tailored according to
the characteristics and preference of patients provided
optimal outcome in a raw clinical scenario. The use of
proportional doses provided a prompt response in most
patients. The treatment was safe and eﬀective, and only a
minority of patients required further treatment. Drugs were
given by trained nurses autonomously evaluating BTP and
following the prescription as needed, ordered on the clinical
sheet, according to the proportionality between the dose as
needed and the background analgesics. A certain dose is
necessary to cover the majority of BTP events with severe
TABLE 2. Doses and Changes in Pain Intensity in Patients Treated With Different Opioids for BTP Successfully (See Text)
IV-MO OTFC OR-MO IV-ME OS-ME OR-OX
Evaluable episodes 248 124 31 15 4 5
Dose (SD) 14.9 (17.9) 637 (432) 7.5 (2.3) 5.87 (2.96) 10 (0) 5 (0)
T0 Pain intensity 7.2 (0.96) 6.9 (0.74) 6.7 (0.9) 6.9 (1) 7.75 (1.7) 7.14 (0.9)
T15 2.72 (0.9) 2.53 (0.75) 2.39 (0.66) 2.86 (0.6) 3.5 (1.3) 3.4 (3.4)
P 0.0005 0.0005 0.0005 0.0005 0.003 0.001
IV-ME indicates intravenous methadone; IV-MO, intravenous morphine; OR-MO, oral morphine; OR-OX, oral oxycodone; OS-ME, oral methadone;
OTFC, oral transmucosal fentanyl.
TABLE 3. Percentage of Pain Reduction, According to the Opioid
Administered
IV-MO OTFC OR-MO IV-ME OR-ME OX
<33% 7 1 0 0 0 1
33-49% 241 123 31 15 4 4
>50% 225 121 31 13 3 4 FIGURE 1. Cumulative proportion of responders with oral trans-
mucosal fentanyl (OTFC) and intravenous morphine (IV-MO).
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intensity, which may have diﬀerent presentations and un-
predictable courses. It could be argued that this approach
could expose patients to adverse eﬀects. However, no
patient developed severe adverse eﬀects requiring a medical
intervention, including older patients who could potentially
be at risk, regardless of the type of opioid, dose, route, and
age, conﬁrming that tolerance is a protective factor against
the occurrence of severe adverse eﬀects, also explain the
high percentage of successfully treated episodes. Of interest,
oral medications were quite eﬀective. This can be owing
to the doses used (1/5 of the opioid daily dose) or to a
spontaneous pain relief, given that slow onset of any opioid
administered orally.
In some way, the approach described refutes the need
of titration, reported in earlier studies.6–9 This information,
however, was not determined on the basis of a comparison
between titration strategy and no titration strategy12
Despite an enormous interindividual variability, data
pooled from the trials of the OTFC showed a statistically
signiﬁcant relationship between the BTP dose and around-
the-clock dose.11 For instance, in an earlier open controlled
study, IV-MO and OTFC in doses proportional to the
scheduled daily dose of opioids were both safe and eﬀective
in patients experiencing pain exacerbation,10 suggesting
that opioids given as needed could be safely used at
proportional doses, regardless of the modality of adminis-
tration. Preliminary and conﬁrmatory surveys have shown
the safety of this approach in a large number of patients
with no life-threatening adverse eﬀects occurring even in
older patients. Respiratory depression, which is the most
feared adverse eﬀect, has never occurred, and no emergency
call was needed.4,5 Finally, in a recent survey, reproducing
a real clinical scenario, patients receiving a mean oral
morphine dose of 132mg, required 800mg of OTFC,15
suggesting that titration process may provide even higher
doses than those expected by using proportional doses to
basal opioid regimen.
The ﬁndings of this study suggest that in patients,
receiving opioids for chronic cancer pain, the risks of
administering doses of opioids proportional to the basal
opioid regimen, even though relatively high, are minimal,
either with opioids at fast or slow onset of action. This can
be explained by the protective eﬀect oﬀered by opioid
tolerance in patients chronically receiving relevant opioid
doses for the management of the cancer pain.
For an appropriate evaluation of data presented, it
should be taken into account that the setting of this
observational study typically reﬂects the real clinical
situation occurring in an acute palliative care unit, rather
than that of a controlled study. The choice of opioids to be
administered as needed was based on clinical and practical
considerations, or patient’s convenience; data gathered
provide useful information about diﬀerent modalities of
opioid administration for BTP. The ﬁndings of this audit
suggest that opioid doses for BTP could be based on the
basal opioid regimen. This approach could prevent the need
of titration that reduces patients’ compliance.15,16 This
approach cannot be generalized, owing to the character-
istics of the unit, and this hypothesis should be tested in
other settings and other contexts. Simplifying the treatment
could help both patients and professionals. Controlled
studies of diﬀerent strategies to choice the opioid doses for
treating BTP, for example, titration versus nontitration
methods, should provide deﬁnitive information on this
challenging issue.
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